Maxim Kuzin1,2, Georgios Schoretsanitis1,2,3, Ekkehard Haen4,5, Benedikt Stegmann4,5, Christoph Hiemke6,7, Gerhard Gründer1,2, Michael Paulzen8,9,10. 1. Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany. 2. JARA, Translational Brain Medicine, Jülich, Germany. 3. University Hospital of Psychiatry, Bern, Switzerland. 4. Department of Psychiatry and Psychotherapy, Clinical Pharmacology, University of Regensburg, Regensburg, Germany. 5. Department of Pharmacology and Toxicology, University of Regensburg, Regensburg, Germany. 6. Department of Psychiatry and Psychotherapy, University Medical Center of Mainz, Mainz, Germany. 7. Institute of Clinical Chemistry and Laboratory Medicine, University Medical Center of Mainz, Mainz, Germany. 8. Department of Psychiatry, Psychotherapy and Psychosomatics, RWTH Aachen University, Pauwelsstr. 30, 52074, Aachen, Germany. m.paulzen@alexianer.de. 9. JARA, Translational Brain Medicine, Jülich, Germany. m.paulzen@alexianer.de. 10. Alexianer Hospital Aachen, Alexianergraben 33, 52062, Aachen, Germany. m.paulzen@alexianer.de.
Abstract
BACKGROUND AND OBJECTIVE: An increasing trend in prescribing proton pump inhibitors (PPIs) inevitably increases the risk of unwanted drug-drug interactions (DDIs). The aim of this study was to uncover pharmacokinetic interactions between two PPIs-omeprazole and pantoprazole-and venlafaxine. METHODS: A therapeutic drug monitoring database contained plasma concentrations of venlafaxine and its active metabolite O-desmethylvenlafaxine. We considered three groups: a group of patients who received venlafaxine without confounding medications (non-PPI group, n = 906); a group of patients who were comedicated with omeprazole (n = 40); and a group of patients comedicated with pantoprazole (n = 40). Plasma concentrations of venlafaxine, O-desmethylvenlafaxine and active moiety (venlafaxine + O-desmethylvenlafaxine), as well as dose-adjusted plasma concentrations, were compared using non-parametrical tests. RESULTS: Daily doses of venlafaxine did not differ between groups (p = 0.949). The Mann-Whitney U test showed significantly higher plasma concentrations of active moiety, as well as venlafaxine and O-desmethylvenlafaxine, in both PPI groups [p = 0.023, p = 0.011, p = 0.026, +29% active moiety, +27% venlafaxine, +36% O-desmethylvenlafaxine (pantoprazole); p = 0.003, p = 0.039 and p < 0.001, +36% active moiety, +27% venlafaxine, +55% O-desmethylvenlafaxine (omeprazole)]. Significantly higher concentration-by-dose (C/D) values for venlafaxine and active moiety were detected in the pantoprazole group (p = 0.013, p = 0.006, respectively), while in the omeprazole group, C/D ratios for all three parameters-venlafaxine, O-desmethylvenlafaxine and active moiety-were significantly higher (p = 0.021, p < 0.001 and p < 0.001, respectively). CONCLUSIONS: Significantly higher plasma concentrations for all parameters (venlafaxine, O-desmethylvenlafaxine, active moiety) suggest clinically relevant inhibitory effects of both PPIs, most likely on the cytochrome P450 (CYP) 2C19-mediated metabolism of venlafaxine. The findings might be the result of different degrees of CYP2C19 involvement, therefore the inhibition of CYP2C19 by both PPIs may lead to an increased metabolism via CYP2D6 to O-desmethylvenlafaxine.
BACKGROUND AND OBJECTIVE: An increasing trend in prescribing proton pump inhibitors (PPIs) inevitably increases the risk of unwanted drug-drug interactions (DDIs). The aim of this study was to uncover pharmacokinetic interactions between two PPIs-omeprazole and pantoprazole-and venlafaxine. METHODS: A therapeutic drug monitoring database contained plasma concentrations of venlafaxine and its active metabolite O-desmethylvenlafaxine. We considered three groups: a group of patients who received venlafaxine without confounding medications (non-PPI group, n = 906); a group of patients who were comedicated with omeprazole (n = 40); and a group of patients comedicated with pantoprazole (n = 40). Plasma concentrations of venlafaxine, O-desmethylvenlafaxine and active moiety (venlafaxine + O-desmethylvenlafaxine), as well as dose-adjusted plasma concentrations, were compared using non-parametrical tests. RESULTS: Daily doses of venlafaxine did not differ between groups (p = 0.949). The Mann-Whitney U test showed significantly higher plasma concentrations of active moiety, as well as venlafaxine and O-desmethylvenlafaxine, in both PPI groups [p = 0.023, p = 0.011, p = 0.026, +29% active moiety, +27% venlafaxine, +36% O-desmethylvenlafaxine (pantoprazole); p = 0.003, p = 0.039 and p < 0.001, +36% active moiety, +27% venlafaxine, +55% O-desmethylvenlafaxine (omeprazole)]. Significantly higher concentration-by-dose (C/D) values for venlafaxine and active moiety were detected in the pantoprazole group (p = 0.013, p = 0.006, respectively), while in the omeprazole group, C/D ratios for all three parameters-venlafaxine, O-desmethylvenlafaxine and active moiety-were significantly higher (p = 0.021, p < 0.001 and p < 0.001, respectively). CONCLUSIONS: Significantly higher plasma concentrations for all parameters (venlafaxine, O-desmethylvenlafaxine, active moiety) suggest clinically relevant inhibitory effects of both PPIs, most likely on the cytochrome P450 (CYP) 2C19-mediated metabolism of venlafaxine. The findings might be the result of different degrees of CYP2C19 involvement, therefore the inhibition of CYP2C19 by both PPIs may lead to an increased metabolism via CYP2D6 to O-desmethylvenlafaxine.
Authors: Nils Eiel Steen; Monica Aas; Carmen Simonsen; Ingrid Dieset; Martin Tesli; Mari Nerhus; Erlend Gardsjord; Ragni Mørch; Ingrid Agartz; Ingrid Melle; Anja Vaskinn; Olav Spigset; Ole A Andreassen Journal: Schizophr Res Date: 2015-10-26 Impact factor: 4.939
Authors: Michael Paulzen; Ekkehard Haen; Benedikt Stegmann; Christoph Hiemke; Gerhard Gründer; Sarah E Lammertz; Georgios Schoretsanitis Journal: Psychoneuroendocrinology Date: 2016-07-18 Impact factor: 4.905
Authors: Corbin J Bachmeier; David Beaulieu-Abdelahad; Nowell J Ganey; Michael J Mullan; Gary M Levin Journal: Biopharm Drug Dispos Date: 2011-03-28 Impact factor: 1.627
Authors: S M Fogelman; J Schmider; K Venkatakrishnan; L L von Moltke; J S Harmatz; R I Shader; D J Greenblatt Journal: Neuropsychopharmacology Date: 1999-05 Impact factor: 7.853
Authors: Dara J Sakolsky; James M Perel; Graham J Emslie; Gregory N Clarke; Karen Dineen Wagner; Benedetto Vitiello; Martin B Keller; Boris Birmaher; Joan Rosenbaum Asarnow; Neal D Ryan; James T McCracken; Michael J Strober; Satish Iyengar; Giovanna Porta; David A Brent Journal: J Clin Psychopharmacol Date: 2011-02 Impact factor: 3.153
Authors: R Curi-Pedrosa; M Daujat; L Pichard; J C Ourlin; P Clair; L Gervot; P Lesca; J Domergue; H Joyeux; G Fourtanier Journal: J Pharmacol Exp Ther Date: 1994-04 Impact factor: 4.030
Authors: T J Stamm; D Becker; L M Sondergeld; K Wiethoff; C Hiemke; G O'Malley; R Ricken; M Bauer; M Adli Journal: Pharmacopsychiatry Date: 2014-07-23 Impact factor: 5.788
Authors: Amaia Calderón-Larrañaga; Luis A Gimeno-Feliu; Francisca González-Rubio; Beatriz Poblador-Plou; María Lairla-San José; José M Abad-Díez; Antonio Poncel-Falcó; Alexandra Prados-Torres Journal: PLoS One Date: 2013-12-20 Impact factor: 3.240